There is a paucity of information on the effects of electrical dosage in patients who receive ECT. There is marked variability in human seizure threshold, and in the treatment of major depression, stimulus intensity relative to seizure threshold appears to impact substantially on the efficacy and efficiency of ECT, as well as on cognitive side effects. We have replicated earlier results that low dose unilateral ECT (just above seizure threshold) is ineffective, with response rates of 28% and 18% in two independent samples. In contrast, bilateral ECT, in both low and high dose conditions, has resulted in a clinical response rate of ` 70%. Unilateral ECT administered at 150% above seizure threshold has produced an intermediate response rate (47%): clearly superior to low dose unilateral ECT, but inferior to bilateral ECT (low and high dose). Across unilateral and bilateral ECT conditions, higher stimulus dose appears to significantly increase the speed of clinical response. There is also now evidence that it is the degree to which electrical dose exceeds seizure threshold, and not the absolute dose given, that impacts on efficacy and side effect profiles. In recent years there has been flowing uncertainty about the relative efficacy of unilateral ECT. These new findings indicate that depending on dosage factors, the efficacy of unilateral ECT can vary markedly. The flow and ceiling for such effects are unknown, and dose- response functions for unilateral ECT need to be determined. This is of particular clinical relevance given the superiority of unilateral ECT, at traditional dose levels, in cognitive side effects. This proposed study will use a random-assignment, double-blind, four-group design in 120 patients with major depression to compare right unilateral ECT at three dosage levels: 50%, 150% and 450% above seizure threshold, with a bilateral group treated at 150% above seizure threshold serving as a standard for efficacy and side effect comparisons. The study will provide information as to which of these unilateral ECT conditions may be preferred in clinical practice, based on the tradeoff between efficacy and side effects. In determining such relations, alternative measures for ECT stimulus quantification will be evaluated, as well as new methods for dose quantification. It is hypothesized that efficacy and objective cognitive side effects will show incremental changes at each of the unilateral ECT dose levels, and that the high dose unilateral condition will be equivalent to the moderate dose bilateral condition in efficacy, but will still retain advantages with respect to side effect profiles. In examining neurobiological effects of stimulus dosing in unilateral ECT, it is hypothesized that enhanced stimulus intensity results in greater anterior (frontal) cortical changes in EEG measures, without impact on asymmetry, and in greater ictal subcortical generalization, resulting in a steeper acute prolactin surge and greater ictal and interictal global EEG delta activity. This research is designed to address the questions of where in the dosing range unilateral ECT is optimized and, when optimized, how does this treatment compare to bilateral ECT.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH035636-09
Application #
3566191
Study Section
Treatment Development and Assessment Research Review Committee (TDA)
Project Start
1988-08-01
Project End
1995-07-31
Budget Start
1990-09-01
Budget End
1991-07-31
Support Year
9
Fiscal Year
1990
Total Cost
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Sackeim, Harold A (2014) Autobiographical memory and electroconvulsive therapy: do not throw out the baby. J ECT 30:177-86
Prudic, Joan; Haskett, Roger F; McCall, W Vaughn et al. (2013) Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT 29:3-12
McCall, W Vaughn; Reboussin, David; Prudic, Joan et al. (2013) Poor health-related quality of life prior to ECT in depressed patients normalizes with sustained remission after ECT. J Affect Disord 147:107-11
Devanand, Devangere; Lee, Joseph; Luchsinger, Jose et al. (2013) Lessons from epidemiologic research about risk factors, modifiers, and progression of late onset Alzheimer's Disease in New York City at Columbia University Medical Center. J Alzheimers Dis 33 Suppl 1:S447-55
McCall, W Vaughn; Rosenquist, Peter B; Kimball, James et al. (2011) Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. J ECT 27:97-102
Brakemeier, Eva-Lotta; Berman, Robert; Prudic, Joan et al. (2011) Self-evaluation of the cognitive effects of electroconvulsive therapy. J ECT 27:59-66
Devanand, D P; Van Heertum, Ronald L; Kegeles, Lawrence S et al. (2010) (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease. Am J Geriatr Psychiatry 18:959-72
Devier, Deidre J; Pelton, Gregory H; Tabert, Matthias H et al. (2009) The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease. Int J Geriatr Psychiatry 24:1335-42
Sackeim, Harold A; Dillingham, Elaine M; Prudic, Joan et al. (2009) Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry 66:729-37
Payne, Nancy A; Prudic, Joan (2009) Electroconvulsive therapy: Part II: a biopsychosocial perspective. J Psychiatr Pract 15:369-90

Showing the most recent 10 out of 118 publications